- Home
- SST vs PSTV Comparison
SST vs PSTV Comparison
Compare SST & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | PSTV |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 61.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SST | PSTV |
|---|---|---|
| Price | $4.39 | $0.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $7.25 |
| AVG Volume (30 Days) | 29.7K | ★ 6.2M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | $5,258,000.00 |
| Revenue This Year | N/A | $28.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.16 |
| 52 Week High | $15.00 | $2.31 |
Technical Indicators
Market Signals| Indicator | SST | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 53.15 |
| Support Level | $4.05 | $0.61 |
| Resistance Level | $5.00 | $0.76 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 43.92 | 39.44 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).